Allergies News and Research

Latest Allergies News and Research

Cancer drug allergies

Cancer patients from the Southeastern United States who are treated with the drug cetuximab, known commercially as Erbitux, are far more likely to suffer severe allergic reactions than patients in other regions of the country.

14 Mar 2008

Aspirin cuts asthma risk in women

A small dose of aspirin on alternate days can cut the risk of developing asthma among women, suggests a large study, published ahead of print in Thorax.

14 Mar 2008

Researchers find cause of severe allergic reaction to cetuximab

Clinicians have been perplexed by the fact that some patients given the drug cetuximab - an immune-based therapy commonly used to treat persons diagnosed with head and neck cancer, or colon cancer - have a severe and rapid adverse reaction to the drug.

13 Mar 2008

Nasal polyps from analgesics

If a patient develops respiratory problems after taking analgesics, this indicates that the active substances are poorly tolerated.

11 Mar 2008

Femara helps protect against return of breast cancer after completing Tamoxifen therapy

Women may reduce the risk of their breast cancer returning by starting treatment with Femara (letrozole tablets) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published in the Journal of Clinical Oncology.

11 Mar 2008

Tackling antimicrobial resistance

Drug resistance is making many diseases increasingly difficult and sometimes impossible to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

11 Mar 2008

Allergy testing is essential in the effective management of patients with allergic conditions

When combined with a detailed medical history, it can identify the causes of allergy symptoms and provide the basis for avoidance, environmental control and immunotherapy.

11 Mar 2008

Clearer understanding on how allergy symptoms are triggered

A team of Penn State University researchers is the first to demonstrate that lipid molecules in cell membranes participate in mammals' reactions to allergens in a living cell.

10 Mar 2008

Theories about preventing childhood allergies questioned

When it comes to preventing food allergies in children two new studies are saying that many methods currently in practice may be ineffective.

10 Mar 2008

Indoor allergen exposure a great importance in relation to asthma

Results from a new national survey demonstrate that elevated allergen levels in the home are associated with asthma symptoms in allergic individuals.

3 Mar 2008

Forest Laboratories to develop and distribute the novel beta blocker Bystolic (nebivolol)

Mylan Inc. has announced that it and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic (nebivolol), which is currently approved in the United States for the treatment of hypertension.

28 Feb 2008

Nanoemulsion vaccines show increasing promise

A novel technique for vaccinating against a variety of infectious diseases - using an oil-based emulsion placed in the nose, rather than needles - has proved able to produce a strong immune response against smallpox and HIV in two new studies.

27 Feb 2008

Tenofovir gel safe for daily use over an extended period

A vaginal microbicide that incorporates an antiretroviral (ARV) drug normally used to treat people with HIV is safe for sexually active HIV-negative women to use every day over an extended period, suggest results of a clinical trial of tenofovir topical gel.

27 Feb 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

XYNTHA approved for teatment of hemophilia A by FDA

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE) , announced today that it has received approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis.

22 Feb 2008

FDA approves XYZAL (levocetirizine dihydrochloride) for allergies and chronic idiopathic urticaria

UCB and sanofi-aventis have announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.

20 Feb 2008

CT scan can harm kidneys, but cheap drug can help

As more and more Americans undergo CT scans and other medical imaging scans involving intense X-rays, a new study suggests that many of them should take a pre-scan drug that could protect their kidneys from damage.

20 Feb 2008

Discovery of antibody that neutralizes two viruses classified as henipaviruses

In laboratory experiments, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues supported by the NIH National Institute of Allergy and Infectious Disease (NIAID), have discovered an antibody that neutralizes two viruses classified as henipaviruses.

18 Feb 2008

Role gound for glaucoma gene and a signaling pathway

Researchers have found that a gene and a related signaling pathway play a role in the development of glaucoma, which is a common cause of visual impairment and blindness worldwide.

18 Feb 2008

Protein found in the saliva of deer ticks prevents the HIV-1 virus from attaching to the surface of T cells

The HIV-1 virus cripples the human immune system by targeting white blood cells called T cells that form the body's first line of defense in fighting infections.

17 Feb 2008